Teewinot Capital Advisers’s Quest Diagnostics DGX Stock Holding History

Teewinot Capital Advisers’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87M	Sell	18,251 -10,374	-36%	-$2.04M	0.28%	24
2026 Q1	$5.61M	Buy	28,625 +10,506	+58%	+$2.04M	0.45%	23
2025 Q4	$3.14M	Hold	18,119	–	–	0.23%	26
2025 Q3	$3.45M	Buy	18,119 +9,445	+109%	+$1.68M	0.27%	26
2025 Q2	$1.56M	Sell	8,674 -3,947	-31%	-$686K	0.13%	29
2025 Q1	$2.14M	Buy	+12,621	New	+$2.07M	0.22%	28

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Teewinot Capital Advisers's DGX Position: Q2 2026 in Review

Teewinot Capital Advisers reduced its Quest Diagnostics (DGX) stake by 36% in Q2 2026, selling an estimated $2.04M and leaving 18,251 shares worth $3.87M. The position accounts for 0.28% of the portfolio, ranked #24.

Teewinot Capital Advisers first reported a position in DGX in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.61M in Q1 2026. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Teewinot Capital Advisers held 18,251 shares of Quest Diagnostics worth $3.87M as of Q2 2026.
Teewinot Capital Advisers sold 10,374 Quest Diagnostics shares in Q2 2026, an estimated $2.04M.
Quest Diagnostics made up 0.28% of Teewinot Capital Advisers's portfolio in Q2 2026, its #24 holding.
Teewinot Capital Advisers first reported a position in Quest Diagnostics in Q1 2025 and has held it in 6 quarters since.
Teewinot Capital Advisers's Quest Diagnostics position peaked at $5.61M in Q1 2026.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Teewinot Capital Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.